CA3150267A1 - Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof - Google Patents

Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof Download PDF

Info

Publication number
CA3150267A1
CA3150267A1 CA3150267A CA3150267A CA3150267A1 CA 3150267 A1 CA3150267 A1 CA 3150267A1 CA 3150267 A CA3150267 A CA 3150267A CA 3150267 A CA3150267 A CA 3150267A CA 3150267 A1 CA3150267 A1 CA 3150267A1
Authority
CA
Canada
Prior art keywords
crystalline form
cancer
compound
pyridin
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3150267A
Other languages
English (en)
French (fr)
Inventor
Stephane L. Raeppel
Franck Raeppel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of CA3150267A1 publication Critical patent/CA3150267A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA3150267A 2019-09-10 2020-09-09 Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof Pending CA3150267A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962898469P 2019-09-10 2019-09-10
US62/898,469 2019-09-10
PCT/US2020/049986 WO2021050580A1 (en) 2019-09-10 2020-09-09 Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof

Publications (1)

Publication Number Publication Date
CA3150267A1 true CA3150267A1 (en) 2021-03-18

Family

ID=74866002

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3150267A Pending CA3150267A1 (en) 2019-09-10 2020-09-09 Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof

Country Status (6)

Country Link
US (1) US12466838B2 (enExample)
EP (1) EP4027999A4 (enExample)
JP (2) JP2022546861A (enExample)
CN (1) CN114401720A (enExample)
CA (1) CA3150267A1 (enExample)
WO (1) WO2021050580A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202302597A (zh) * 2021-03-10 2023-01-16 美商米拉蒂醫療公司 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途
WO2022240802A1 (en) 2021-05-10 2022-11-17 Teva Pharmaceuticals International Gmbh Solid state forms of sitravatinib salts and processes for preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2091910T3 (pl) * 2006-12-06 2015-02-27 Conatus Pharmaceuticals Inc Postacie krystaliczne kwasu (3S)-3-[N-(N’-(2-tert-butylofenylo)oksamylo)alaninylo]amino-5-(2’,3’,5’,6’-tetrafluorofenoksy)-4-oksopentanowego
MX2010002427A (es) * 2007-08-29 2010-03-30 Methylgene Inc Inhibidores de actividad de la proteina tirosina cinasa.
US8907091B2 (en) * 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
US20180237378A1 (en) * 2015-08-19 2018-08-23 Sandoz Ag Asymmetric Bisamidation of Malonic Ester Derivatives
EP3740491A1 (en) * 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN109384799B (zh) * 2018-11-12 2020-07-14 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物

Also Published As

Publication number Publication date
WO2021050580A1 (en) 2021-03-18
EP4027999A4 (en) 2023-08-16
US20220402936A1 (en) 2022-12-22
JP2022546861A (ja) 2022-11-09
US12466838B2 (en) 2025-11-11
EP4027999A1 (en) 2022-07-20
JP2025102940A (ja) 2025-07-08
CN114401720A (zh) 2022-04-26

Similar Documents

Publication Publication Date Title
KR101860806B1 (ko) 퓨린 유도체의 결정 형태
JP6809681B2 (ja) ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形
CA2793413C (en) Crystal form of edoxaban tosylate monohydrate and method of producing same
TW202115093A (zh) Ｃｆｔｒ調節劑之結晶形式
CA2799744C (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
CN102510855A (zh) N-[3-氟-4-({6-(甲基氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的晶形
KR20090045233A (ko) 속효형 벤조디아제핀 염 및 이의 중합체 형태
JP2025102940A (ja) マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用
CA3222612A1 (en) New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
KR101246392B1 (ko) 술폰아미드 화합물 및 그 결정
US20240317746A1 (en) Crystalline forms of an azetidine parp1 inhibitor
JP2020073523A (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
HK40064763A (en) Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
EP4169915A1 (en) Crystalline form of compound
WO2024245364A1 (en) Solid forms of a macrocyclic farnesyltransferase inhibitor and formulations thereof, and methods of preparing and using the macrocyclic compound and its solid forms
US11787819B2 (en) Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
WO2025252193A1 (en) New polymorphic forms of the shp2 inhibitor and uses thereof
US20240132447A1 (en) Polymorphs of (2s,5r)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid and preparation processes thereof
US20230286900A1 (en) Polymorphic forms of (r)-oxybutynin hydrochloride
WO2025137366A2 (en) Solid-state forms of stat3 inhibitors and methods of use thereof
AU2024289011A1 (en) New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]- 3-fluoro-pyrrolidine-1-sulfonamide
WO2021208850A1 (zh) 硝基咪唑类衍生物及其制备方法和用途
BR122024009277A2 (pt) Formas cristalinas de um composto de triazolopirimidina
EA040317B1 (ru) Кристаллические полиморфные формы свободного основания 2-гидрокси-6-((2-(1-изопропил-1н-пиразол-5-ил)пиридин-3-ил)метокси)бензальдегида